SUMMARY
INTRODUCTION
Insulin-like growth factor-I (IGF-I) mimics many of the metabolic and trophic effects of insulin (1) , suggesting that it could be used in the treatment of diabetes (2) . For instance, IGF-I stimulates glucose uptake in selected clinical situations (3). Metabolic control in patients with extreme insulin resistance is improved after using IGF-I (4). Moreover, patients with type II (non-insulin-dependent) diabetes who received IGF-I therapy show improved glucose tolerance and decreased hyperinsulinemia and hypertriglyceridemia (5) . The effects of IGF-I are mediated through interaction with the type-1 IGF receptor (6), a α 2 β 2 heterotetramer closely related to the insulin receptor (7, 8) . In blood and interstitial fluids, free IGF concentration is exceedingly low because most of the IGFs are associated with one or more of six high affinity IGF-binding proteins (IGFBPs), which mask the action of the IGFs (9) . The predominant IGFBP in blood circulation is IGFBP-3 which, together with an 80 kDa acid-labile subunit, form a 150 kDa trimolecular complex (10) and, thus, potentially provides a "reservoir" of biologically inactive IGFs. We hypothesized that if specific ligands could be identified that displace IGF from its binding proteins, the "free" biologically active IGF would be available to interact with its receptors to mimic the activity of exogenously applied IGF-I. This novel approach may have an advantage over exogenous insulin or IGF-I, which has the potential to cause hypoglycemia. Since no exogenous IGF-I is given, hypoglycemia is not likely to occur because a ceiling effect is reached when all the IGFs are released from the circulating IGFBPs. This concept prompted us to set up a screening assay to identify IGFBP-3 ligand inhibitors from our in-house chemical library collection that could displace bioactive IGF-I from its binding protein complex and the results are reported herein.
EXPERIMENTAL PROCEDURES

IGFBP Radioligand-Binding Assay
Human IGFBP-1, BP-2, BP-4, BP-5 and BP-6 cDNA's were used to express the five binding proteins in the BaculoGold Expression System (PharMingen, San Diego, CA) in Sf9 insect cells according to the manufacturer's instruction and the proteins were purified by affinity chromatography on a hIGF-II-coupled Affi-Gel 15 column, followed by reverse-phase HPLC as described (11) . IGFBP-3 was isolated from out-dated human plasma as reported previously (11) . The radioligand-binding assay was performed at room temperature in duplicate in 0.02% NP-40/PBS buffer, pH 7.2. Briefly, for the human IGFBP-3 binding assay, the reaction was started by the addition of 100 µl of buffer, 100 µl of hIGF-I (Sigma, St. Louis, MO) in buffer solution, followed by 100 µl of Ion spray mass spectrometry of NBI-31772 showed a molecular ion at m/z 342 (M+H). In negative charge mode, a parent peak at m/z 340 (M-H) was detected. This implied that the molecular weight of this compound was 341. High-resolution mass spectrometry confirmed the molecular formula as C 17 H 11 NO 7 . An intense absorption band at 3400 cm -1 in FT-IR spectrometry indicated the presence of carboxylic acid and hydroxyl groups in NBI-31772. Also, absorption at 1640 cm -1 in conjunction with two 13 C NMR signals at δ 194.5 and 167.9 (Table I) implied the presence of a conjugated ketone carbonyl group and a carboxylic acid carbonyl group in NBI-31772. NMR signal at δ 167.9) at C3. Thus, the complete structure of NBI-31772 was deduced as 1-(3,4-dihydroxybenzoyl)-3-hydroxycarbonyl-6,7-dihydroxyisoquinoline shown in Fig. 1 towards the six human IGFBPs determined in this study (see Table I ) is similar to the values reported in the literature (12) .
To demonstrate that NBI-31772 could release bioactive IGF-I from its bound form with IGFBP-3, we employed a cell proliferation assay using 3T3 fibroblasts (13) 
